What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ligand Pharmaceuticals Inc (LGND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 127,994 | $25,554,038 | -3% | 0.01% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 7,315 | $1,460,440 | 0.01% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.67 | 5,523 | $583,629.22 | 161,234 | 2025-05-09 | Filing | |
| $104.53 | 2,307 | $241,149.56 | 155,711 | 2025-05-09 | Filing | |
| $104.57 | 1,680 | $175,677.60 | 153,404 | 2025-05-09 | Filing | |
| $104.40 | 500 | $52,200.00 | 27,932 | 2025-05-09 | Filing | |
| $103.89 | 1,000 | $103,890.00 | 27,432 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $234.02 | 800 | $187,214.16 | 41,382 | 2026-05-01 | Filing | |
| $232.92 | 1,420 | $330,749.24 | 42,182 | 2026-05-01 | Filing | |
| $232.04 | 780 | $180,991.12 | 43,602 | 2026-05-01 | Filing | |
| $230.87 | 370 | $85,421.60 | 44,382 | 2026-05-01 | Filing | |
| $229.71 | 98 | $22,511.44 | 44,752 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,100,267 | $219,668,307 | 0.01% | |
| 2. | 848,089 | $169,320,969 | 0% | |
| 3. | 561,675 | $112,138,378 | 3.02% | |
| 4. | 504,637 | $100,750,777 | 0.72% | |
| 5. | 494,670 | $98,760,866 | 1.35% |
News See All
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2025 Earnings Call Transcript
Melanie Herman: Good morning, everyone, and welcome to Ligand's Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript August 7, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript May 8, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Ligand's Third Quarter 2024 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
13 Most Promising Small-Cap Stocks According to Analysts
In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts.
Hedge Fund Resource Center